USA flag logo/image

An Official Website of the United States Government

STTR Phase I: Intelligent Low-Toxicity Nanoparticles for Cancer Diagnosis and…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
91237
Program Year/Program:
2009 / STTR
Agency Tracking Number:
0930673
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NanoScale Materials, Inc.
1310 Research Park Drive Manhattan, KS -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: STTR Phase I: Intelligent Low-Toxicity Nanoparticles for Cancer Diagnosis and Treatment
Agency: NSF
Contract: 0930673
Award Amount: $150,000.00
 

Abstract:

This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). This Small Business Technology Transfer (STTR) Phase I project focuses on synthesis and delivery of nanoparticles for determination of the progression of cancer. Besides diagnosis, the nanoplatform offers the treatment option of directing high- temperature therapy specifically to the tumor, without harming healthy tissue. The nanoplatform contains a central iron/iron oxide/gold core/shell nanoparticle, plus the ability to identify which of four cancer-specific enzymes in the patient?s body are abnormally active. The activity of these four enzymes indicates the progression of cancer (Stage I, Stage II, Stage III, or Stage IV). The broader impacts of this research are earlier diagnosis of cancer, and more effective treatment of cancer. Cancer is the second largest cause of death in developed countries, accounting for nearly 20% of all deaths. Early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis is detection of tumors at an early stage for maximum therapeutic benefit. An example is breast cancer where mammography requires more than a million cells for accurate clinical diagnosis. Offering better techniques to cancer centers and their patients could detect these abnormalities in the hundreds to thousands of cells stage, greatly improving treatment success. The functionalized nanoparticles will be more selective towards cancer cells than currently available technology, enabling diagnosis by spectroscopic methods including MRI at earlier stages of the cancers progression. In addition to enabling earlier detection, these materials also have potential for breakthroughs in treatment methods.

Principal Investigator:

Franklin O. Kroh
PhD
7855370179
fkroh@nanoscalecorp.com

Business Contact:

Franklin O. Kroh
PhD
7855370179
fkroh@nanoscalecorp.com
Small Business Information at Submission:

NANOSCALE MATERIALS INC
1310 RESEARCH PARK DR MANHATTAN, KS 66502

EIN/Tax ID: 481172548
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Kansas State University
2 Fairchild Hall
Manhattan, KS 66506 1103
Contact: Paul Lowe
Contact Phone: (785) 532-6817
RI Type: Nonprofit college or university